News | June 10, 2007

Cardio BioSciences Licenses Mayo Clinic’s Cardiac Stem Cell Technology

June 11, 2007 — Cardio BioSciences and Mayo Clinic announced today that they have entered into a collaborative agreement related to the licensing of Mayo Clinic research, know-how and intellectual property in the field of cardiac commitment of stem cells, in a move that positions Cardio_ BioSciences as a global leader in the field of regenerative therapies for heart failure

The research, headed by Andre Terzic, MD, PhD and Atta Behfar, M.D., at Mayo Clinic, has focused on the guided commitment of adult as well as embryonic stem cells. The scope of the license covers heart failure of ischemic and non-ischemic origin.

“This opportunity positions Cardio BioSciences as a global leader in the field of regenerative therapies for heart failure,” said Christian Homsy, MD, CEO of Cardio_ BioSciences. “The agreement includes existing intellectual property and a commitment to ongoing collaborative research projects in early-development stages at Mayo Clinic.”

“Over one million Americans suffer a new or recurrent heart attack each year. Despite the aggressive approaches we use to treat heart patients, no effective means are available to repair a damaged heart,” added Terzic. “Discoveries by the Mayo team open new therapeutic avenues exploiting the regenerative potential of stem cells guided toward cardiac lineage. We are excited about translating this novel methodology into repair strategies.”

For more information: www.cardio3bio.com and www.mayoclinic.com

Related Content

News | Stem Cell Therapies| October 24, 2017
October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate compani
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
SanBio Receives $20 Million Grant for Stroke Clinical Trial
News | Stroke| July 12, 2017
July 12, 2017 — SanBio Inc.

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.

 

News | Stem Cell Therapies| June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina
News | Stem Cell Therapies| May 12, 2017
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a...
3-D Printed Patch Can Help Mend a ‘Broken’ Heart

This photo shows the 3D-bioprinted cell patch in comparison to a mouse heart. When the patch was placed on a live mouse following a simulated heart attack, the researchers saw significant increase in functional capacity after just four weeks. Image courtesy of Patrick O’Leary, University of Minnesota.

News | Stem Cell Therapies| April 18, 2017
April 18, 2017 — A team of biomedical engineering researchers, led by the University of Minnesota, has created a revo
Texas Heart Institute, ischemic heart failure, adult stem cell therapy, CONCERT-HF clinical trial
News | Stem Cell Therapies| February 03, 2017
Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to...
Overlay Init